cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis

American Journal of Pathology

Volumn 162, Issue 3, 2003, Pages 991-1000

  Anders, Robert A ^a   Yerian, Lisa M ^a   Tretiakova, Maria ^a   Davison, Jon M ^a   Quigg, Richard J ^a   Domer, Peter H ^a   Hoberg, Jamie ^a   Hart, John ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; COMPLEMENTARY DNA; LIGAND; PROTEIN TYROSINE KINASE; SEMAPHORIN;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; DYSPLASIA; EARLY DIAGNOSIS; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; LIVER REGENERATION; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

EID: 0037372343     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63893-X     Document Type: Article

References (65)

1. Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P, Kerr DJ: Hepatocellular carcinoma. Ann Oncol 2001, 12:161-172
2. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z: Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002, 21:2593-2604
3. Laurent-Puig P, Legoix P, Bluteau O, Belghitl J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J: Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120:1763-1773
4. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562
5. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345:41-52
6. Komanduri S, Cotler S: Hepatitis C. Clin Perspect Gastroenterol 2002, (March/April):91-99
7. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwandee T, Lin HJ, Barbosa L: Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001, 33:455-463
8. Terada T, Terasaki S, Nakanuma Y: A clinicopathologic study of adenomatous hyperplasia of the liver in 209 consecutive cirrhotic livers examined by autopsy. Cancer 1993, 72:1551-1556
9. Furuya K, Nakamura M, Yamamoto Y, Togei K, Otsuka H: Macroregenerative nodule of the liver. A clinicopathologic study of 345 autopsy cases of chronic liver disease. Cancer 1988, 61:99-105
10. Sun M, Eshleman JR, Ferrell LD, Jacobs G, Sudilovsky EC, Tuthill R, Hussein MR, Sudilovsky O: An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001, 33:1415-1424
11. Thung SN, Hytiroglou P, Fiel I, Theise N: Preneoplastic lesions in chronic hepatitis C. Princess Takamatsu Symp 1995, 25:171-178
12. Hytiroglou P, Theise ND, Schwartz M, Mor E, Miller C, Thung SN: Macroregenerative nodules in a series of adult cirrhotic liver explants: issues of classification and nomenclature. Hepatology 1995, 21:703-708
13. Ferrell L, Wright T, Lake J, Roberts J, Ascher N: Incidence and diagnostic features of macroregenerative nodules vs. small hepatocellular carcinoma in cirrhotic livers. Hepatology 1992, 16:1372-1381
14. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M: Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995, 21:650-655
15. Matsuno Y, Hirohashi S, Furuya S, Sakamoto M, Mukai K, Shimosato Y: Heterogeneity of proliferative activity in nodule-in-nodule lesions of small hepatocellular carcinoma. Jpn J Cancer Res 1990, 81:1137-1140
16. Oda T, Tsuda H, Sakamoto M, Hirohashi S: Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett 1994, 83:197-200
17. Sakamoto M, Hirohashi S, Shimosato Y: Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991, 22:172-178
18. Thomas RM, Berman JJ, Yetter RA, Moore GW, Hutchins GM: Liver cell dysplasia: a DNA aneuploid lesion with distinct morphologic features. Hum Pathol 1992, 23:496-503
19. International Working Party: Terminology of nodular hepatocellular lesions. Hepatology 1995, 22:983-993
20. Gerard CJ, Olsson K, Ramanathan R, Reading C, Hanania EG: Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res 1998, 58:3957-3964
21. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868
22. Nguyen U: GeneSpring Advanced Analysis Techniques, chapter 2. Redwood City, CA, Silicon Genetics, 2000
23. Gong Y, Cui L, Minuk GY: Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28s-ribosomal RNA gene expression in human hepatocellular carcinoma. Hepatology 1996, 23:734-737
24. Omori M, Omori N, Evarts RP, Teramoto T, Thorgeirsson SS: Coexpression of flt-3 ligand/flt-3 and SCF/c-kit signal transduction system in bile-duct-ligated SI and W mice. Am J Pathol 1997, 150:1179-1187
25. Monga SP, Tang Y, Candotti F, Rashid A, Wildner O, Mishra B, Iqbal S, Mishra L: Expansion of hepatic and hematopoietic stem cells utilizing mouse embryonic liver explants. Cell Transplant 2001, 10:81-89
26. Tessier-Lavigne M, Goodman CS: The molecular biology of axon guidance. Science 1996, 274:1123-1133
27. Martin-Satue M, Blanco J: Identification of semaphorin E gene expression in metastatic human lung adenocarcinoma cells by mRNA differential display. J Surg Oncol 1999, 72:18-23
28. Hirose M: The role of Wilms' tumor genes. J Med Invest 1999, 46:130-140
29. Scharf JG, Dombrowski F, Ramadori G: The IGF axis and hepatocarcinogenesis. Mol Pathol 2001, 54:138-144
30. Norstedt G, Levinovitz A, Moller C, Eriksson LC, Andersson G: Expression of insulin-like growth factor I (IGF-I) and IGF-II mRNA during hepatic development, proliferation and carcinogenesis in the rat. Carcinogenesis 1988, 9:209-213
31. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, Czech MP, Ullrich A, Brechot C: Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988, 48:6844-6849
32. Hahn E, Wick G, Pencev D, Timpl R: Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut 1980, 21:63-71
33. Milani S, Herbst H, Schuppan D, Hahn EG, Stein H: In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells. Hepatology 1989, 10:84-92
34. Jezequel AM, Ballardini G, Mancini R, Paolucci F, Bianchi FB, Orlandi F: Modulation of extracellular matrix components during dimethylnitrosamine-induced cirrhosis. J Hepatol 1990, 11:206-214
35. Fine SW, Lisanti MP, Galbiati F, Li M: Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 2001, 115:719-724
36. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK: Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001, 58:811-814
37. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, Sers C: Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001, 159:1635-1643
38. Hsia CC, Di Bisceglie AM, Kleiner Jr DE, Farshid M, Tabor E: RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. J Med Virol 1994, 44:67-73
39. Zheng L, Lee WH: The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp Cell Res 2001, 264:2-18
40. Ichihara T, Komagata Y, Yang XL, Uezato T, Enomoto K, Koyama K, Miyazaki J, Sugiyama T, Miura N: Resistance to fulminant hepatitis and carcinogenesis conferred by overexpression of retinoblastoma protein in mouse liver. Hepatology 2001, 33:948-955
41. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR: A receptor tyrosine kinase specific to hematopoletic stem and progenitor cell-enriched populations. Cell 1991, 65:1143-1152
42. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D: Murlne Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 1991, 6:1641-1650
43. Lyman SD, Stocking K, Davison B, Fletcher F, Johnson L, Escobar S: Structural analysis of human and murine flt3 ligand genomic loci. Oncogene 1995, 11:1165-1172
44. Lyman SD, James L, Escobar S, Downey H, de Vries P, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS: Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene 1995, 10:149-157
45. Smith JR, Thackray AM, Bujdoso R: Reduced herpes simplex virus type 1 latency in Flt-3 ligand-treated mice is associated with enhanced numbers of natural killer and dendritic cells. Immunology 2001, 102:352-358
46. Chen H, He Z, Tessier-Lavigne M: Axon guidance mechanisms: semaphorins as simultaneous repellents and anti-repellents. Nat Neurosci 1998, 1:436-439
47. Yamada T, Endo R, Gotoh M, Hirohashi S: Identification of semaphorin E as a non-MDR drug resistance gene of human cancers. Proc Natl Acad Sci USA 1997, 94:14713-14718
48. Mangasser-Stephan K, Dooley S, Welter C, Mutschler W, Hanselmann RG: Identification of human semaphorin E gene expression in rheumatoid synovial cells by mRNA differential display. Biochem Biophys Res Commun 1997, 234:153-156
49. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, Thompson TC: Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000, 19:3256-3265
50. Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997, 8:45-62
51. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, Yumoto E, Higashi T, Tsuji T: Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 2002, 176:149-158
52. Scharf JG, Ramadori G, Dombrowski F: Analysis of the IGF axis in preneoplastic hepatic foci and hepatocellular neoplasms developing after low-number pancreatic islet transplantation into the livers of streptozotocin diabetic rats. Lab Invest 2000, 80:1399-1411
53. Villafuerte BC, Koop BL, Pao CI, Phillips LS: Glucocorticoid regulation of insulin-like growth factor-binding protein-3. Endocrinology 1995, 136:1928-1933
54. Scharf JG, Knittel T, Dombrowski F, Muller L, Saile B, Braulke T, Hartmann H, Ramadori G: Characterization of the IGF axis components in isolated rat hepatic stellate cells. Hepatology 1998, 27:1275-1284
55. Yamamoto T, Kaneda K, Hirohashi K, Kinoshita H, Sakurai M: Sinusoidal capillarization and arterial blood supply continuously proceed with the advance of the stages of hepatocarcinogenesis in the rat. Jpn J Cancer Res 1996, 87:442-450
56. Macluskey M, Chandrachud LM, Pazouki S, Green M, Chisholm DM, Ogden GR, Schor SL, Schor AM: Apoptosis, proliferation, and angiogenesis in oral tissues. Possible relevance to tumour progression. J Pathol 2000, 191:368-375
57. Lee CS, Redshaw A, Boag G: Abnormalities in type IV collagen immunoreactivity in human laryngeal cancers. Pathology 1996, 28:135-138
58. Sheela S, Barrett JC: Degradation of type IV collagen by neoplastic human skin fibroblasts. Carcinogenesis 1985, 6:173-179
59. Zeng ZS, Cohen AM, Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999, 20:749-755
60. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001, 61:2129-2137
61. Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K: Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001, 120:955-966
62. Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, Cai T, Zhang X, Xiao HS, Qu J, Liu F, Huang QH, Cheng ZH, Li NG, Du JJ, Hu W, Shen KT, Lu G, Fu G, Zhong M, Xu SH, Gu WY, Huang W, Zhao XT, Hu GX, Gu JR, Chen Z, Han ZG: Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001, 98:15089-15094
63. Noguchi K, Enjoji M, Nakamuta M, Nakashima M, Nishi H, Choi I, Taguchi K, Kotoh K, Shimada M, Sugimachi K, Tsuneyoshi M, Nawata H, Watanabe T: Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. Cancer Lett 2001, 168:197-202
64. Ng IO, Liu CL, Fan ST, Ng M: Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 2000, 113:355-363
65. Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, Nakagawa K, Shimizu H, Yokosuka O, Nakajima N: Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001, 78:110-115